Filament Health Corp.
OTCPK:FLHL.F Stock Report
Filament Health Balance Sheet Health
Financial Health criteria checks 4/6 Filament Health has a total shareholder equity of CA$3.2M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$4.7M and CA$1.5M respectively.
Key information Interest coverage ratio n/a Cash CA$1.34m Equity CA$3.18m Total liabilities CA$1.54m Total assets CA$4.73m
Recent financial health updates
Show all updates Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital Jun 14
Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder
Filament Health Corp. Announces Change to Board of Directors May 06 Filament Health Corp. Announces Chief Financial Officer Changes
Filament Health Corp. Completes the First Export of Botanical Psilocybin to Israel Feb 15
Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders Jan 31 Filament Health Corp. announced that it has received CAD 0.9 million in funding from Negev Capital Dec 07
Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder Oct 11 Filament Health Corp. announced that it expects to receive CAD 2 million in funding from Negev Capital Oct 01
Filament Health Corp., Annual General Meeting, Nov 07, 2023 Sep 26
Filament Health Corp. Announces FDA Approval of Two Clinical Trials Studying Its Biological Psychedelic Drug Candidate PEX010 Aug 09 Filament Health Corp. announced that it has received CAD 2.5 million in funding from Negev Capital Jul 25
Filament Health Announces Clinical Trial Approval in Partnership with Psychiatric Centre Copenhagen Jan 19
Filament Health Corp. Announces Change to Board of Directors Dec 31
Filament Health Corp. and Atma Journey Centers Inc. Announce 14 Subjects Dosed in Health Canada-Approved Psilocybin Clinical Trial Sep 02
Filament Health Corp. Announces the Appointment of Dr. Konstantin Adamsky to Board of Directors, and Jeff Chilton of Nammex to the Advisory Council Aug 25
Filament Health Corp. Announces Eighth Patent Issuance Aug 18 Filament Health Corp. announced that it has received CAD 2.50008 million in funding from North American Medicinal Mushroom Extracts, Negev Capital Jul 14
Filament Health Corp. Receives Third Patent by United States Patent and Trademark Office Jul 13
Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial Jul 08
Filament Health Announces Sixth Patent Issuance Jul 07 Filament Health Corp. announced that it expects to receive CAD 2.50008 million in funding from North American Medicinal Mushroom Extracts, Negev Capital Jul 01
Filament Health Corp. Announces Patient Dosing Through Health Canada Special Access Program Jun 17
Filament Health Corp. Cultivates 70th Variety of Psilocybin-containing Mushrooms At Its 3,500 Square Foot Gmpcompliant Facility in Metro Vancouver Jun 11
Filament Health Corp. Issues Second Patent by United States Patent and Trademark Office May 19
Filament Health Corp., Annual General Meeting, Jun 28, 2022 May 07
Filament Health Corp. and Cybin Therapeutics Announce Approval for Phase Ii Clinical Trial for Depression Feb 01
Filament Health Corp. Announces Health Canada Approval for Phase II Clinical Trial Administering New Psilocybin Microdose Formulation Jan 05
Financial Position Analysis
Short Term Liabilities: FLHL.F's short term assets (CA$2.0M) exceed its short term liabilities (CA$1.4M).
Long Term Liabilities: FLHL.F's short term assets (CA$2.0M) exceed its long term liabilities (CA$171.9K).
Debt to Equity History and Analysis
Debt Level: FLHL.F is debt free.
Reducing Debt: FLHL.F had no debt 5 years ago.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FLHL.F has less than a year of cash runway based on its current free cash flow .
Forecast Cash Runway: FLHL.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.4% each year
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}